A Phase 3 Study With Asunaprevir and Daclatasvir (DUAL) for Null or Partial Responders to Peginterferon Alfa and Ribavirin (P/R), Intolerant or Ineligible to P/R Subjects and Treatment-Naive Subjects With Chronic Hepatitis C Genotype 1b Infection
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Asunaprevir (Primary) ; Daclatasvir (Primary) ; Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Registrational; Therapeutic Use
- Acronyms Hallmark-DUAL
- Sponsors Bristol-Myers Squibb
- 01 Jun 2018 Results (n=1239) of pooled analysis (NCT01012895, NCT01030432, NCT01051414, NCT01497834 and NCT01581203) published in the Infectious Diseases and Therapy
- 09 Jul 2015 Results published in the Advances in Therapy.
- 14 Oct 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.